-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:ATO公布2026财年第二季度稀释后每股收益为3.47美元,高于去年同期的3.03美元(增长14.5%),净利润增长19.8%至5.82亿美元;年初至今每股收益为5.92美元,高于去年同期的5.26美元(增长12.5%)。本季度强劲的业绩反映了公司持续执行其成熟的投资战略,该战略专注于系统现代化,分销和管道及存储业务均实现了稳健增长。管理层将2026财年稀释后每股收益预期从8.15-8.35美元上调至8.40-8.50美元,这反映了公司对其覆盖八个州的监管执行情况充满信心。资本支出为10亿美元,增长19.5%,其中89%的年初至今支出用于提升安全性和可靠性。公司已落实价值 1.361 亿美元的监管合规成果,另有价值 5.984 亿美元的合规成果正在多个司法管辖区推进中。董事会宣布将年度股息提高 14.9%,至每股 4.00 美元。我们认为,澳大利亚税务局 (ATO) 审慎的资本配置策略将继续推动运营改进和监管合规方面的复苏。
Related Articles
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.